Advertisement

Topics

Transvenous Lead Removal Post-Market Clinical Study

2018-10-03 08:24:23 | BioPortfolio

Published on BioPortfolio: 2018-10-03T08:24:23-0400

Clinical Trials [1589 Associated Clinical Trials listed on BioPortfolio]

The Role of Electrophysiology Testing in Survivors of Unexplained Cardiac Arrest

Sudden cardiac death (SCD) remains a major cause of mortality within developed nations despite aggressive efforts to reduce its societal burden. Despite extensive clinical and genetic inve...

Multicenter Imaging in Lead Extraction Study

The primary objectives of this registry is to correlate the amount of fibrosis as documented on Electrocardiogram (ECG) gated Computed Tomography (CT) scans with ease of advancing sheaths ...

Safety and Performance of LeadExx LC System in Lead Extraction

The study's main purpose is to evaluate the safety and performance of the LeadExx LC System and its ability to safely extract leads. The study will enroll 10 patients scheduled for CIED l...

Bridge Occlusion Balloon in Lead Extraction Procedure

To evaluate the use of an occlusion balloon (Bridge™ Occlusion Balloon, Spectranetics) within the Superior Vena Cava in lead extraction patients.

HEAL-HF: A Cardiac Resynchronization Therapy (CRT) Outcomes Study

The literature shows that approximately 40% of individuals who receive a cardiac resynchronization therapy (CRT) device for symptomatic congestive heart failure (CHF) do not have a clinica...

PubMed Articles [11800 Associated PubMed Articles listed on BioPortfolio]

Transvenous lead extraction in patients with cardiac resynchronization therapy devices is not associated with increased 30-day mortality.

Transvenous lead extraction (TLE) may be necessary due to system infection/erosion or lead malfunction. Cardiac resynchronization therapy (CRT) patients undergoing TLE may be at greater risk due to in...

Major cardiac and vascular complications after transvenous lead extraction: acute outcome and predictive factors from the ESC-EHRA ELECTRa (European Lead Extraction ConTRolled) registry.

We aimed at describing outcomes and predictors of cardiac avulsion or tear (CA/T) with tamponade and vascular avulsion or tear (VA/T) after transvenous lead extraction (TLE) in the ESC-EHRA European L...

Cephalic vs. subclavian lead implantation in cardiac implantable electronic devices: a systematic review and meta-analysis.

Cephalic vein cutdown (CVC) and subclavian puncture (SP) are widely used techniques for lead insertion of cardiac implantable electronic devices (CIEDs). Whether one technique is superior to the other...

Procedural outcomes associated with transvenous lead extraction in patients with abandoned leads: an ESC-EHRA ELECTRa (European Lead Extraction ConTRolled) Registry Sub-Analysis.

The decision to abandon or extract superfluous leads remains controversial. We sought to compare procedural outcome of patients with and without abandoned leads undergoing transvenous lead extraction ...

Successful percutaneous lead extraction 15 years after a failed extraction attempt.

Medical and Biotech [MESH] Definitions

The study of the electrical activity and characteristics of the HEART; MYOCARDIUM; and CARDIOMYOCYTES.

A state of elevated cardiac output due to conditions of either increased hemodynamic demand or reduced cardiac oxygen output. These conditions may include ANEMIA; ARTERIOVENOUS FISTULA; THYROTOXICOSIS; PREGNANCY; EXERCISE; FEVER; and ANOXIA. In time, compensatory changes of the heart can lead to pathological form of high cardiac output and eventual HEART FAILURE.

Use of various chemical separation and extraction methods, such as SOLID PHASE EXTRACTION; CHROMATOGRAPHY; and SUPERCRITICAL FLUID EXTRACTION; to prepare samples for analytical measurement of components.

Autosomal dominant syndrome characterized by cardiac and cutaneous MYXOMAS; LENTIGINOSIS (spotty pigmentation of the skin), and endocrinopathy and its associated endocrine tumors. The cardiac myxomas may lead to SUDDEN CARDIAC DEATH and other complications in Carney complex patients. The gene coding for the PRKAR1A protein is one of the causative genetic loci (type 1). A second locus is at chromosome 2p16 (type 2).

Types of artificial pacemakers with implantable leads to be placed at multiple intracardial sites. They are used to treat various cardiac conduction disturbances which interfere with the timing of contraction of the ventricles. They may or may not include defibrillating electrodes (IMPLANTABLE DEFIBRILLATORS) as well.

More From BioPortfolio on "Transvenous Lead Removal Post-Market Clinical Study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial